Aging and Bronchiolitis Obliterans Syndrome Linked to More Interalveolar Pores
Investigators found that aging and bronchiolitis obliterans syndrome are both associated with increased interalveolar communications.
Obstructive Lung Disease
What Affects Prescription Adherence of Patients With Obstructive Lung Disease?
This studied focused on primary prescription adherence for obstructive lung diseases among adult patients in primary care over a 3-year period.
Trikafta Approval Expanded to Include Younger Cystic Fibrosis Patients
The approval was based on data from a phase 3 study that evaluated Trikafta in 66 children 6 to 11 years of age with CF who were either homozygous for the F508del mutation or heterozygous for the F508del mutation and 1 minimal function mutation.
Assessing the Risk of SARS-CoV-2 Infection in Patients With Cystic Fibrosis
While a subset of people with cystic fibrosis may experience a more severe clinical course of COVID-19, they are not at an increased risk of contracting SARS-CoV-2 compared with the general population.
Elexacaftor/Tezacaftor/Ivacaftor Improved Lung Function in Cystic Fibrosis
Combination therapy with elexacaftor/tezacaftor/ivacaftor resulted in clinically significant improvements in lung function in patients with cystic fibrosis.
Predictors of Failed Pseudomonas aeruginosa Eradication in Children With Cystic Fibrosis
Investigators sought to determine whether resistance to antibiotic treatment was associated with failed eradication therapy in patients with cystic fibrosis.
Cystic Fibrosis Updates in Care: Part I — Current State of Treatment
In honor of Cystic Fibrosis Awareness Month, we present a 2-part series on treatment updates and developments in the field.
Cystic Fibrosis Updates in Care: Part II — The “Sweat Sticker” and Clinician Q&A
In honor of Cystic Fibrosis Awareness Month, we present a 2-part series on treatment updates in the field, including the “sweat sticker.”
Lumacaftor-Ivacaftor Safe, Effective for Long-Term Treatment of Cystic Fibrosis
Lumacaftor-ivacaftor is generally safe and well tolerated for long-term treatment of children with cystic fibrosis homozygous for the F508del-CFTR mutation.
Digital Tomosynthesis Effectively Estimates Structural Lung Disease in Cystic Fibrosis
Digital tomosynthesis of the chest offers effective quantitative estimation of structural lung disease in patients with cystic fibrosis.
- Loading...
Loading...
Next post in Obstructive Lung Disease
Loading... 
Loading...